Insider Buying: Coya Therapeutics, Inc. (NASDAQ:COYA) Insider Acquires 2,710 Shares of Stock

Coya Therapeutics, Inc. (NASDAQ:COYA) insider Fred Grossman acquired 2,710 shares of the business’s stock in a transaction on Monday, November 11th. The shares were bought at an average price of $7.37 per share, with a total value of $19,972.70. Following the completion of the transaction, the insider now directly owns 2,710 shares of the company’s stock, valued at approximately $19,972.70. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Coya Therapeutics Stock Down 0.1 %

Shares of NASDAQ:COYA opened at $7.24 on Thursday. Coya Therapeutics, Inc. has a 12-month low of $4.75 and a 12-month high of $10.69. The company’s 50 day moving average price is $7.10 and its two-hundred day moving average price is $7.02. The firm has a market cap of $120.98 million, a PE ratio of -11.14 and a beta of 0.46.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. On average, research analysts expect that Coya Therapeutics, Inc. will post -1.27 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. GHP Investment Advisors Inc. bought a new stake in Coya Therapeutics during the third quarter worth about $169,000. Renaissance Technologies LLC bought a new stake in shares of Coya Therapeutics during the 2nd quarter worth approximately $101,000. Gilbert & Cook Inc. acquired a new stake in shares of Coya Therapeutics during the 2nd quarter worth approximately $61,000. Finally, Vanguard Group Inc. increased its stake in Coya Therapeutics by 772.3% in the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after acquiring an additional 750,338 shares during the last quarter. Institutional investors own 39.75% of the company’s stock.

Wall Street Analyst Weigh In

COYA has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday. Chardan Capital reiterated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Thursday, November 7th.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.